{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:22:27Z","timestamp":1790738547336,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The American Trial Using Tranexamic Acid (TXA) in Thrombocytopenia (A-TREAT, NCT02578901) demonstrated no superiority of TXA over placebo in preventing World Health Organization (WHO) grade 2 or higher bleeding in patients with severe thrombocytopenia requiring supportive platelet transfusion following myeloablative therapy for hematologic disorders. In this ancillary study, we sought to determine whether this clinical outcome could be explained on the basis of correlative assays of fibrinolysis. Plasma was collected from A-TREAT participants (n\u00a0= 115) before the initiation of study drug (baseline) and when TXA was at steady-state trough concentration (follow-up). Global fibrinolysis was measured by 3 assays: euglobulin clot lysis time (ECLT), plasmin generation (PG), and tissue-type plasminogen activator (tPA)\u2013challenged clot lysis time (tPA-CLT). TXA was quantified in follow-up samples by tandem mass spectrometry. Baseline samples did not demonstrate fibrinolytic activation by ECLT or tPA-CLT. Furthermore, neither ECLT nor levels of plasminogen activator inhibitor-1, tPA, plasminogen, alpha2-antiplasmin, or plasmin-antiplasmin complexes were associated with a greater risk of WHO grade 2+ bleeding. TXA trough concentrations were highly variable (range, 0.7-10 \u03bcg\/mL) and did not correlate with bleeding severity, despite the fact that plasma TXA levels correlated strongly with pharmacodynamic assessments by PG (Spearman r,\u00a0\u22120.78) and tPA-CLT (r, 0.74). We conclude that (1) no evidence of fibrinolytic activation was observed in these patients with thrombocytopenia, (2) trough TXA concentrations varied significantly between patients receiving the same dosing schedule, and (3) tPA-CLT and PG correlated well with TXA drug levels.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008255","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T17:03:38Z","timestamp":1661965418000},"page":"900-908","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Absence of hyperfibrinolysis may explain lack of efficacy of\u00a0tranexamic acid in hypoproliferative thrombocytopenia"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7669-0760","authenticated-orcid":false,"given":"Anton","family":"Ilich","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC"},{"name":"2UNC Blood Research Center, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry B.","family":"Gernsheimer","sequence":"additional","affiliation":[{"name":"3Department of Medicine\/Hematology and Seattle Cancer Care Alliance, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell J.","family":"Triulzi","sequence":"additional","affiliation":[{"name":"4Department of Pathology, University of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Herren","sequence":"additional","affiliation":[{"name":"5Department of Biostatistics, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4774-3122","authenticated-orcid":false,"given":"Siobhan P.","family":"Brown","sequence":"additional","affiliation":[{"name":"5Department of Biostatistics, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Holle","sequence":"additional","affiliation":[{"name":"2UNC Blood Research Center, University of North Carolina School of Medicine, Chapel Hill, NC"},{"name":"6Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8678-5985","authenticated-orcid":false,"given":"Andrew T.","family":"Lucas","sequence":"additional","affiliation":[{"name":"7Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9596-1944","authenticated-orcid":false,"given":"Bas","family":"de Laat","sequence":"additional","affiliation":[{"name":"8Synapse Research Institute, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahed","family":"El Kassar","sequence":"additional","affiliation":[{"name":"9Division of Blood Diseases and Resources, National Heart Lung and Blood Institute, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2845-2303","authenticated-orcid":false,"given":"Alisa S.","family":"Wolberg","sequence":"additional","affiliation":[{"name":"2UNC Blood Research Center, University of North Carolina School of Medicine, Chapel Hill, NC"},{"name":"6Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3601-7432","authenticated-orcid":false,"given":"Susanne","family":"May","sequence":"additional","affiliation":[{"name":"5Department of Biostatistics, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8930-4304","authenticated-orcid":false,"given":"Nigel S.","family":"Key","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC"},{"name":"2UNC Blood Research Center, University of North Carolina School of Medicine, Chapel Hill, NC"},{"name":"6Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"issue":"2","key":"2023081516041807500_bib1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.thromres.2014.11.012","article-title":"Tranexamic acid--an old drug still going strong and making a revival","volume":"135","author":"Tengborn","year":"2015","journal-title":"Thromb Res"},{"issue":"5","key":"2023081516041807500_bib2","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3324\/haematol.2020.250720","article-title":"The never ending success story of tranexamic acid in acquired bleeding","volume":"105","author":"Franchini","year":"2020","journal-title":"Haematologica"},{"issue":"21","key":"2023081516041807500_bib3","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMoa2201171","article-title":"Tranexamic acid in patients undergoing noncardiac surgery","volume":"386","author":"Devereaux","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10241","key":"2023081516041807500_bib4","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)30848-5","article-title":"Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial","volume":"395","author":"HALT-IT Trial Collaborators","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"2023081516041807500_bib5","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S1474-4422(20)30369-0","article-title":"Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial","volume":"19","author":"Meretoja","year":"2020","journal-title":"Lancet Neurol"},{"issue":"10269","key":"2023081516041807500_bib6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0140-6736(20)32518-6","article-title":"Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial","volume":"397","author":"Post","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2023081516041807500_bib7","doi-asserted-by":"crossref","first-page":"e625","DOI":"10.1097\/HS9.0000000000000625","article-title":"Tranexamic acid is not a universal hemostatic agent","volume":"5","author":"Schutgens","year":"2021","journal-title":"Hemasphere"},{"issue":"1-2","key":"2023081516041807500_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/10428199509059668","article-title":"A\u00a0controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia","volume":"19","author":"Shpilberg","year":"1995","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2023081516041807500_bib9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/ejh.13555","article-title":"Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: a Dutch nationwide survey","volume":"106","author":"Cornelissen","year":"2021","journal-title":"Eur J Haematol"},{"issue":"3","key":"2023081516041807500_bib10","first-page":"CD009733","article-title":"Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders","volume":"3","author":"Estcourt","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2023081516041807500_bib11","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/blood.2022016308","article-title":"Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo controlled, randomized clinical trial","volume":"140","author":"Gernsheimer","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023081516041807500_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/rth2.12275","article-title":"Development and application of global assays of hyper- and hypofibrinolysis","volume":"4","author":"Ilich","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"2023081516041807500_bib13","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/jth.13656","article-title":"Development of Shiny app tools to simplify and standardize the analysis of hemostasis assay data: communication from the SSC of the ISTH","volume":"15","author":"Longstaff","year":"2017","journal-title":"J\u00a0Thromb Haemostasis"},{"issue":"1","key":"2023081516041807500_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/jth.15114","article-title":"Application of a plasmin generation assay to define pharmacodynamic effects of tranexamic acid in women undergoing cesarean delivery","volume":"19","author":"Miszta","year":"2021","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"2023081516041807500_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.thromres.2021.05.017","article-title":"Euglobulin clot lysis time reveals a high frequency of fibrinolytic activation in trauma","volume":"204","author":"Ilich","year":"2021","journal-title":"Thromb Res"},{"issue":"1","key":"2023081516041807500_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/rth2.12293","article-title":"Assessing plasminogen activation potential with global fibrinolytic assays","volume":"4","author":"Urano","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2023081516041807500_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1055\/a-1325-0268","article-title":"Measuring Fibrinolysis","volume":"41","author":"Longstaff","year":"2021","journal-title":"H\u00e4mostaseologie"},{"issue":"3","key":"2023081516041807500_bib18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0887-7963(87)70020-0","article-title":"The role of the hematocrit in bleeding","volume":"1","author":"Boneu","year":"1987","journal-title":"Transfus Med Rev"},{"key":"2023081516041807500_bib19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev-fluid-010814-014513","article-title":"Fluid mechanics of blood clot formation","volume":"47","author":"Fogelson","year":"2015","journal-title":"Annu Rev Fluid Mech"},{"issue":"4","key":"2023081516041807500_bib20","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood.V91.4.1469","article-title":"Acute bleeding after bone marrow transplantation (BMT)- incidence and effect on survival. A quantitative analysis in 1,402 patients","volume":"91","author":"Nevo","year":"1998","journal-title":"Blood"},{"issue":"5","key":"2023081516041807500_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00062752-200109000-00009","article-title":"Acute bleeding complications in patients after bone marrow transplantation","volume":"8","author":"Nevo","year":"2001","journal-title":"Curr Opin Hematol"},{"issue":"7","key":"2023081516041807500_bib22","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023081516041807500_bib23","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.hoc.2016.01.002","article-title":"Platelet transfusions in patients with hypoproliferative thrombocytopenia: conclusions from clinical trials and current controversies","volume":"30","author":"Crighton","year":"2016","journal-title":"Hematol Oncol Clin N Am"},{"issue":"9734","key":"2023081516041807500_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial","volume":"376","author":"Shakur","year":"2010","journal-title":"Lancet"},{"issue":"9771","key":"2023081516041807500_bib25","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(11)60278-X","article-title":"The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial","volume":"377","author":"Roberts","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"2023081516041807500_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17100","article-title":"The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients","volume":"17","author":"Roberts","year":"2013","journal-title":"Health Technol Assess"},{"issue":"10084","key":"2023081516041807500_bib27","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(17)30638-4","article-title":"Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial","volume":"389","author":"WOMAN Trial Collaborators","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"2023081516041807500_bib28","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1111\/jth.15046","article-title":"Tranexamic acid in acute gastrointestinal bleeding - a cautionary tale","volume":"18","author":"Roberts","year":"2020","journal-title":"J\u00a0Thromb Haemostasis"},{"issue":"9","key":"2023081516041807500_bib29","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1111\/bcp.14767","article-title":"Population pharmacokinetics and pharmacodynamics of tranexamic acid in women undergoing caesarean delivery","volume":"87","author":"Li","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2023081516041807500_bib30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ijlh.12688","article-title":"Global assays of fibrinolysis","volume":"39","author":"Ilich","year":"2017","journal-title":"Int J Lab Hematol"},{"issue":"suppl 6","key":"2023081516041807500_bib31","first-page":"S86","article-title":"Viscoelastic testing in oncology patients (including for the diagnosis of fibrinolysis): review of existing evidence, technology comparison, and clinical utility","volume":"60","author":"Walsh","year":"2020","journal-title":"Transfusion"},{"issue":"4","key":"2023081516041807500_bib32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/ijlh.12331","article-title":"Rotation thromboelastometry analysis of clot formation and fibrinolysis in severe thrombocytopenia: effect of fibrinogen, activated prothrombin complex concentrate, and thrombin- activatable fibrinolysis inhibitor","volume":"37","author":"Shenkman","year":"2015","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"2023081516041807500_bib33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.12078","article-title":"The incidence and magnitude of fibrinolytic activation in trauma patients","volume":"11","author":"Raza","year":"2013","journal-title":"J\u00a0Thromb Haemostasis"},{"issue":"2","key":"2023081516041807500_bib34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1055\/s-0036-1598001","article-title":"Diagnosis and treatment of hyperfibrinolysis in trauma (a European perspective)","volume":"43","author":"Gall","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"2023081516041807500_bib35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0028-2243(87)90156-0","article-title":"The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid","volume":"24","author":"Dockeray","year":"1987","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"8","key":"2023081516041807500_bib36","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1471-0528.1993.tb14272.x","article-title":"Endometrial fibrinolytic enzymes in women with normal menstruation and dysfunctional uterine bleeding","volume":"100","author":"Gleeson","year":"1993","journal-title":"Br J Obstet Gynaecol"},{"issue":"9","key":"2023081516041807500_bib37","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/jth.12645","article-title":"No increased systemic fibrinolysis in women with heavy menstrual bleeding","volume":"12","author":"Wiewel-Verschueren","year":"2014","journal-title":"J\u00a0Thromb Haemostasis"},{"issue":"4","key":"2023081516041807500_bib38","first-page":"CD000249","article-title":"Antifibrinolytics for heavy menstrual bleeding","volume":"4","author":"Bryant-Smith","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2023081516041807500_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/asheducation-2016.1.10","article-title":"Acute promyelocytic leukemia: preventing early complications and late toxicities","volume":"2016","author":"Abedin","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2023081516041807500_bib40","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1055\/s-0041-1725099","article-title":"Altered fibrinolysis in hematological malignances","volume":"47","author":"B\u00f8nl\u00f8kke","year":"2021","journal-title":"Semin Thromb Hemost"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2023010270","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/6\/900\/2071627\/blooda_adv-2022-008255-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/6\/900\/2071627\/blooda_adv-2022-008255-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T16:19:14Z","timestamp":1692116354000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/6\/900\/486463\/Absence-of-hyperfibrinolysis-may-explain-lack-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,3,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008255","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2023010270","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]}}}